Scott T. Tagawa, MD

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine and urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian/Weill Cornell Medical Center, discusses data from the

phase II TROPHY-U-O1 trial in patients with metastatic urothelial cancer

These data demonstrated that a cohort of patients with metastatic disease who had progressed on platinum-based regimens or immunotherapy experienced an overall response rate (ORR) of 29% with treatment of sacituzumab govitecan. These were heavily pretreated patients, who received an average of 4 prior lines of therapy, says Tagawa.

Videos

Scott T. Tagawa, MD, discusses data from the phase II TROPHY-U-O1 trial in patients with metastatic urothelial cancer, presented at the ESMO Congress 2019.

Use of Sacituzumab Govitecan in Metastatic Urothelial Carcinoma

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine & urology at Weill Cornell Medicine, associate attending physician, NewYork-PresbyterianWeill Cornell Medical Center, discusses benefits and limitations of radium-223 dichloride (Xofigo) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Radium-223 is an effective drug that has some remaining challenges, Tagawa says. It is a great drug because it targets the bone, which is the site of significant problems for the majority of men with mCRPC. Bone metastases can lead to symptoms or, ultimately, death. The downside is that radium-223 only targets the bone, so the natural tendency is to want to combine the drug with other types of therapy. Retrospective studies have suggested that radium-223 in combination with androgen receptor targeted agents is beneficial, but ARROW-223 demonstrated a high rate of fractures with abiraterone acetate (Zytiga) and radium-223 upfront at the same time.

Scott T. Tagawa, MD, Richard A. Stratton Associate Professor in Hematology and Oncology, associate professor of clinical medicine &amp; urology at Weill Cornell Medicine, associate attending physician, NewYork-Presbyterian&ndash;Weill Cornell Medical Center, discusses benefits and limitations of radium-223 in metastatic castration-resistant prostate cancer.

Benefits and Limitations of Radium-223 in mCRPC

Scott T. Tagawa, MD, assistant professor of medicine, medical director, Genitourinary Oncology Research Program, Weill Cornell Medical College, discusses results from a trial that evaluated tumor-directed PET imaging of bone metastases in metastatic castration-resistant prostate cancer (mCRPC) when using the Zr-89 labeled anti-prostate specific membrane antigen (PSMA) antibody J591.

Following standard CT/MRI, bone scintigraphy, and FDG PET imaging, 5 mCi of Zr-89-J591 was administered intravenously and Zr-89-J591 was imaged 6-8 days after injection

The study showed that using J591 PET/CT detects bone disease at greater rates than any other imaging modality tested

A number of sites that were negative on CT, bone scan, and standard FDG PET imaging were positive by J591. A biopsy confirmed that they were positive

Scott T. Tagawa, MD | Authors

Articles

Use of Sacituzumab Govitecan in Metastatic Urothelial Carcinoma

Benefits and Limitations of Radium-223 in mCRPC

Evaluating Tumor-Directed PET Imaging of mCRPC Bone Metastases Using Zr-89-J591